TY  - GEN
AU  - Jatoi,Aminah
AU  - Dakhil,Shaker R
AU  - Foster,Nathan R
AU  - Ma,Cynthia
AU  - Rowland,Kendrith M
AU  - Moore,Dennis F
AU  - Jaslowski,Anthony J
AU  - Thomas,Sachdev P
AU  - Hauge,Mark D
AU  - Flynn,Patrick J
AU  - Stella,Philip J
AU  - Alberts,Steven R
TI  - Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B)
SN  - 1556-1380
PY  - 2008///0703
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Boronic Acids
KW  - administration & dosage
KW  - Bortezomib
KW  - Carboplatin
KW  - Cardia
KW  - pathology
KW  - Disease Progression
KW  - Esophageal Neoplasms
KW  - drug therapy
KW  - Esophagogastric Junction
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Paclitaxel
KW  - Pyrazines
KW  - Stomach Neoplasms
KW  - Survival Rate
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1097/JTO.0b013e31816de276
ER  -